{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-005216","form_type":"8-K","ticker":"INBS","cik":"0001725430","company_name":"INTELLIGENT BIO SOLUTIONS INC.","filed_at":"2023-02-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.326170+00:00","generated_at":"2026-06-19T11:43:26.273224+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Intelligent Bio Solutions Q2 net loss narrows to $0.42M; govt support income up 52%","bullets":["Net loss of $0.42M ($0.46/shr) vs $3.46M ($4.65/shr) in prior year period.","Government support income rose 52% to $269,625 on R&D qualifying expenditures.","Cash and equivalents $2.9M at quarter-end; successful completion of Milestone 7 biosensor phase.","Milestone 7 achieved 4x improvement in time-to-result, enabling under-one-minute test.","Partnered with Boughey Distribution and Hozelock for fingerprint drug testing programs."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-005216","json":"https://secwatch.observer/filing/0001493152-23-005216.json","markdown":"https://secwatch.observer/filing/0001493152-23-005216.md","text":"https://secwatch.observer/filing/0001493152-23-005216.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1725430/000149315223005216/0001493152-23-005216-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1725430/000149315223005216/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T11:43:26.273224+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"64f625103ce7efe1fd692318dc95157052d97302","claim":"INTELLIGENT BIO SOLUTIONS INC. reported fiscal second quarter ended December 31, 2022 results: net income $0.42 million or $0.46 per share, EPS $0.46 per share.","evidence_excerpt":"For the quarter that ended December 31, 2022, the Company had a net loss of $0.42 million or $0.46 per share","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1725430/000149315223005216/0001493152-23-005216-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fiscal second quarter ended December 31, 2022"},{"label":"Net income","value":"$0.42 million or $0.46 per share"},{"label":"EPS","value":"$0.46 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}